<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Jun.07 — Biogen CEO Michel Vounatsos discusses the implications of the FDA’s approval of the company’s controversial Alzheimer’s disease therapy, which will be sold under the name Aduhelm. He speaks on “Bloomberg Markets: The Close.
...read full article on Bloomberg Markets and Finance
